Introduction: There is a paucity of data evaluating whether a multidisciplinary conference coordinating surgery, chemotherapy and radiation therapy translates into better patient care. This article compares the experiences of patients with lung cancer before and after the formation of a prospective, multidisciplinary thoracic malignancy care conference (TMC). Methods: The records of patients with a non-small-cell lung cancer at a tertiary care hospital were reviewed for completeness of staging, multidisciplinary evaluation prior to the initiation of therapy, time from pathologic diagnosis to treatment, multimodality therapy and adherence to national treatment guidelines. The summary data of patients treated before and after the TMC were initiated, and then compared. Results: Between 2001 and 2007, 535 patients were treated prior to the initiation of the TMC and 687 patients within the TMC. The number of patients receiving a complete staging evaluation (79%/93%: p < 0.0001), multidisciplinary evaluation prior to therapy (62%/96%: p < 0.0001) and adherence to the National Comprehensive Cancer Network (NCCN) treatment guidelines (81%/97%: p < 0.0001) all increased significantly while mean days from diagnosis to treatment significantly decreased (29/17: p < 0.0001) following the initiation of a TMC. Conclusion: A multidisciplinary thoracic malignancy conference increased the percentage of patients receiving complete staging, a multidisciplinary evaluation and adherence to nationally accepted care guidelines while decreasing the interval from diagnosis to treatment significantly. While the ultimate goal of treatment is to improve patient survival, the surrogate variables examined in this review indicate that patients with non-small-cell lung cancer benefit from being evaluated in a prospective, multidisciplinary care conference. #
Introduction
Multidisciplinary care conferences and clinics for patients with carcinoma of the lung and bronchus involving physicians specialising in medical and radiation oncology, pulmonary medicine, thoracic surgery, radiology and pathology are becoming more common as the care of these patients has become more frequent and complex. Intuitively appealing, there is a paucity of published information delineating any specific value-added features of such a conference or its optimal form [1] . This investigation summarises our experience treating patients with lung cancer comparing those treated before and after the establishment of a prospective, multidisciplinary care conference.
Materials and methods
All patients treated for carcinoma of the lung and bronchus at a tertiary care medical centre between January 2001 and December 2007 were identified using the institution's tumour registry. The institution's Institutional Review Board waived individual patient consent for this investigation. A retrospective analysis of these patients' records was then performed. Demographic data, completeness of staging, multidisciplinary evaluation prior to the initiation of therapy, time from pathologic diagnosis to treatment and adherence to the National Comprehensive Cancer Network (NCCN) treatment guidelines in effect at the time of diagnosis were all assessed [2] .
Two study groups were populated based on whether a patient had their care prospectively coordinated through the institution's multidisciplinary thoracic malignancy care conference or were diagnosed and treated prior to the conference's establishment. Presentation of the patient at a traditional, retrospective tumour board was not considered equivalent to the prospective thoracic malignancy care conference. Patients who refused all forms of treatment following their diagnosis were also excluded from this analysis. Analysis of data was carried out using GraphPad Prism software 4 A minimum of a computer-aided tomographic imaging study of the chest, including the upper abdomen and adrenal glands, mediastinoscopy and/or positron emission tomography, bronchoscopy, complete blood count, electrolyte profile, pulmonary function tests, further evaluation of any specific symptoms and imaging specific for superior sulcus tumours when indicated.
Multidisciplinary evaluation prior to the initiation of therapy
At minimum, an evaluation by a thoracic surgeon, pulmonologist and medical oncologist for patients with a clinical stage I or II malignancy or evaluation by the above as well as radiation oncology for stage III or IV patients.
Adherence to NCCN guidelines
Compliance with the NCCN guidelines for the staging and treatment of non-small-cell lung cancer (NSCLC) in effect at the time of diagnosis. Patients who refused recommended studies or therapies were counted as being in compliance with the guidelines as long as documentation existed. Similarly, patients whose performance status or other factors prevented them from participating in a particular form of therapy indicated by the guidelines were not counted as deficiencies as long as alternative therapy was offered.
Days from diagnosis to treatment
This interval was defined in days from the time of pathologic diagnosis until the initiation of any treatment (chemotherapy, radiation therapy or surgery).
Results
Between January 2001 and December 2004, 569 patients were diagnosed with NSCLC at the study institution prior to the initiation of a thoracic malignancy care conference. Subsequently, 729 patients were diagnosed with NSCLC from January 2005 through December 2007 and were presented prospectively to a bimonthly care conference, which included thoracic surgeons, medical and radiation oncologists, pulmonary medicine and radiology physicians. Of these patients, 535 and 687 patients, respectively, met this investigation's entrance criteria and were included for analysis.
Demographic data for the two groups are summarised in Table 1 and are comparable. Specifically, patient age, the distribution of tumour histology and tumour stage did not differ significantly between the two groups. The number of patients who refused recommended therapy also did not differ between the two groups.
Significant differences between the two patient groups, however, can be demonstrated and are indicated in Table 2 . Specifically, patients who received a complete staging evaluation using appropriate imaging and/or invasive techniques prior to the initiation of treatment, patients who received a multidisciplinary evaluation, defined as an assessment from a thoracic surgeon, pulmonologist, medical and radiation oncologist, prior to treatment and patients whose care was within the standards of the NCCN practice guidelines were significantly more frequent in patients presented at the thoracic malignancy care conference. Patients who were presented in the thoracic malignancy care conference were also found to have a significantly shorter mean interval from the initial pathologic diagnosis to the initiation of treatment when compared to patients diagnosed before the establishment of the conference.
While the number of patients undergoing surgery with curative intent and the number of patients undergoing a complete surgical resection (R 0 ) did not differ significantly between the two groups, subset analysis found that a higher percentage of patients with stage IIIA NSCLCA underwent surgery in the multidisciplinary conference group (Table 3) . Similarly, although the overall number of patients receiving chemotherapy for less than stage IIIB NSCLCA did not differ significantly between the two groups, patients whose care was coordinated through the multidisciplinary conference were more likely to receive neo-adjuvant chemotherapy when compared to patients whose care was not (Table 2) . Patients undergoing non-therapeutic thoracotomy or thoracscopy did not vary significantly between the two groups. The number of patients undergoing surgical staging procedure(s) did vary significantly favouring multidisciplinary conference patients (Table 3) , which was despite no significant difference being realised in the divergence of patients' clinical versus pathologic stage. The majority of these patients underwent mediastinoscopy as opposed to thoracoscopy. Operative mortality did not differ significantly between the two patient populations.
Although not reaching statistical significance, three other differences were identified between the two patient groups (Table 2) . Patients receiving palliative and/or hospice care were more frequent among patients presented at the thoracic malignancy care conference. Similarly, a higher percentage of patients presented at the conference were enrolled in local, national or international research protocols than patients treated before the conference was established. Finally, patients with a malignant pleural or pericardial effusion were more likely to be treated surgically with or without additional systemic or radiation therapy after the establishment of the conference.
Discussion
Patients with many forms of solid organ malignancy now undergo more than one form of treatment. Patients with NSCLC, for example, may require a combination of surgery, systemic chemotherapy and external beam radiotherapy. Such multimodality treatment can be simultaneous or consecutive, palliative or with curative intent and can involve multiple physicians over the course of months or years.
As thoracic surgeons, medical and radiation oncologists and other physicians and non-physicians become involved in the care of such patients, developing a treatment plan that encompasses the expertise of all these providers becomes complex. Without proper coordination, patients may suffer from differences in the opinions of physicians who, within the standard of normal practice variation, approach the diagnosis, staging and treatment of patients with NSCLC differently. The unintended results can be excessive imaging studies, inaccurate staging assignment, significant delay and/or interruption of treatment, lack of consideration of surgical and non-surgical treatment or palliative options and excessive or inadequate follow-up care.
Success in coordinating the care of other patients with malignant and non-malignant conditions requiring complex care has been reported. Traynor et al., Rasmussen et al. and Steed et al. found significant, specific improvements in the care of patients with amyotrophic lateral sclerosis, spine disorders and chronic wounds, respectively [3] [4] [5] . Patients with amyotrophic lateral sclerosis were also shown to realise a survival advantage after the establishment of a multidisciplinary conference. Similarly, Ducharme et al. found that the use of coordinated multidisciplinary care decreased both the number and length of hospital admissions, while improving the assessed quality of life in patients with congestive heart failure [6] .
Patients with malignancies other than lung cancer have also been shown to benefit from the coordination of multidisciplinary care. Baldwin et al. and Fairchild et al. found measurable benefits in the care of patients with breast cancer, including higher rates of breast conservation, multimodality therapy and pain management [7, 8] . Pawlik et al. similarly found improvements in the care of patients with pancreatic cancer [9] . Specifically, their investigation found that a significant change in a patient's treatment occurred in 25% of cases with the application of a coordinated multidisciplinary approach.
The evaluation of treating patients with lung cancer using a coordinated, multidisciplinary approach has also been underway. Wang et al. and Ouwens et al. found that a significant number of patients being treated for lung cancer required improvements in the quality of their care integration [10, 11] . These authors recommended a multidisciplinary conference or clinic to achieve these goals.
The form of a multidisciplinary care model has also been somewhat defined. Conron et al., for example, reported that within a coordinated multidisciplinary care programme, patients with lung cancer received a timely diagnosis, staging and treatment within evidenced-based guidelines [12] . However, the study did not include a control group for comparison. Wang et al. and Riedel et al. independently found that a multidisciplinary care team must include a representative from medical and radiation oncology as well as thoracic surgery to be effective in improving the care of patients with lung cancer [1, 10] .
Based on the previous discussion, it would seem intuitive that a prospective multidisciplinary care conference would benefit patients with lung cancer. However, the existing literature leaves several unanswered questions. First, are there meaningful differences in the way patients with lung cancer are treated depending on whether a coordinated multidisciplinary care paradigm is used? Second, are physicians and hospitals required to face the challenges of reimbursement, scheduling and resources required to use such an approach in a single clinic as advocated by some? Third, are there any unintended consequences, either positive or negative, associated with such an approach? Only one published investigation attempts to address these questions to date. Leo et al. summarised the outcomes of 344 patients presented at a multidisciplinary lung cancer treatment conference over a 1-year period [13] . They found that the conference produced a high rate of acceptance of a recommended treatment by patients and their primary physicians and resulted in a median time to treatment of 16 days for chemotherapy and 27 days for radiation. Unfortunately, their study did not have the benefit of a control group, did not assess the adequacy of staging or adherence to any standardised treatment guidelines and did not attempt to analyse patients receiving multimodality treatment including neo-adjuvant therapy and surgery. The study did identify a trend for an increase in survival in patients treated using a multidisciplinary care conference, which did not reach statistical significance.
This investigation sought to answer the previously posed questions by comparing two groups of patients with lung cancer treated by the same physicians at a tertiary care hospital either before or after the establishment of a prospective, multidisciplinary care conference. Our findings would appear to support the idea that patients with NSCLC do realise tangible benefits from having their care coordinated through such a conference. These included a more complete staging evaluation, a more frequent multidisciplinary evaluation prior to the initiation of treatment, increased adherence to national care guidelines and a shorter time interval from diagnosis to treatment. Furthermore, although a direct comparison was not made, such a conference appears to be effective without the need to see patients in a multidisciplinary clinic setting with its inherent complexities.
Some unanticipated but intuitive findings were recognised from this study as well. Patients receiving palliative and/or hospice care were more frequent among patients presented at the thoracic malignancy care conference. Similarly, a higher percentage of patients presented at the conference were enrolled in local, national or international research protocols than patients treated before the conference was established. Finally, patients with a malignant pleural or pericardial effusion were more likely to be treated surgically with or without additional systemic or radiation therapy after the establishment of the conference.
Less intuitive results were also identified during our analysis. Despite a significantly higher number of patients receiving operative staging procedures among patients in the multidisciplinary care conference group, divergence between clinical and pathologic staging did not vary significantly between the two patient populations. The lack of recognition of a significant difference in this instance may be the result of a combination of the increase in stage of patients with unrecognised mediastinal lymph node metastases and the decrease in stage of patients with imaging studies, suggestive of mediastinal lymph node metastases diagnosed in each scenario by more frequent mediastinoscopy in the multidisciplinary care group. Similarly, while patients with stage III A disease were more likely to undergo surgery following neo-adjuvant chemoradiation therapy if their care was coordinated by the multidisciplinary conference, this did not result in a significant difference in complete surgical resection, non-therapeutic surgeries or the total number of patients undergoing surgery with curative intent between the two groups. Furthermore, despite the potential increase in surgical mortality associated with neo-adjuvant chemoradiation, no significant difference in operative mortality was realised between the groups.
Although this study is unique in its design and subject, it does have some limitations.
This investigation represents a single institution's experience. Furthermore, the cohort of patients treated prior to the establishment of the care conference was assessed retrospectively, which prevented the inclusion of quality of life and/or patient satisfaction assessments. While the benefits realised appear to be significant, the authors also realise that the ultimate goal in assessing the care of patients with NSCLC is to improve survival, which is not quantifiable at present between the patient groups.
In conclusion, this investigation found compelling evidence that a prospective, multidisciplinary care conference improved the timeliness and quality of care received by patients with NSCLC. Additional benefits of such a conference may include increased accrual to research protocols, more frequent use of palliative and/or hospice care and multidisciplinary palliation. Based on these results, future investigation of the effects of a multidisciplinary care conference on malignancies as well as any impact such a conference may have on resource utilisation, patient satisfaction, overall survival or quality of life are warranted.
